Compare Divis Laboratories with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs JUBILANT LIFE SCIENCES - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES JUBILANT LIFE SCIENCES DIVIS LABORATORIES/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 32.4 14.6 222.3% View Chart
P/BV x 7.3 1.7 429.2% View Chart
Dividend Yield % 0.6 0.9 70.1%  

Financials

 DIVIS LABORATORIES   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
JUBILANT LIFE SCIENCES
Mar-19
DIVIS LABORATORIES/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,142898 127.1%   
Low Rs533618 86.3%   
Sales per share (Unadj.) Rs146.6572.0 25.6%  
Earnings per share (Unadj.) Rs33.036.2 91.2%  
Cash flow per share (Unadj.) Rs38.459.5 64.5%  
Dividends per share (Unadj.) Rs10.004.50 222.2%  
Dividend yield (eoy) %1.20.6 201.1%  
Book value per share (Unadj.) Rs222.8301.9 73.8%  
Shares outstanding (eoy) m265.47159.28 166.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.71.3 431.2%   
Avg P/E ratio x25.320.9 121.2%  
P/CF ratio (eoy) x21.812.7 171.3%  
Price / Book Value ratio x3.82.5 149.7%  
Dividend payout %30.312.4 243.7%   
Avg Mkt Cap Rs m222,318120,694 184.2%   
No. of employees `00010.82.4 450.3%   
Total wages/salary Rs m4,56119,260 23.7%   
Avg. sales/employee Rs Th3,616.038,120.6 9.5%   
Avg. wages/employee Rs Th423.88,058.4 5.3%   
Avg. net profit/employee Rs Th814.92,414.3 33.8%   
INCOME DATA
Net Sales Rs m38,91591,108 42.7%  
Other income Rs m1,134357 317.4%   
Total revenues Rs m40,04991,466 43.8%   
Gross profit Rs m12,61717,390 72.6%  
Depreciation Rs m1,4253,709 38.4%   
Interest Rs m132,198 0.6%   
Profit before tax Rs m12,31311,840 104.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m3,5433,268 108.4%   
Profit after tax Rs m8,7705,770 152.0%  
Gross profit margin %32.419.1 169.9%  
Effective tax rate %28.827.6 104.3%   
Net profit margin %22.56.3 355.8%  
BALANCE SHEET DATA
Current assets Rs m45,35145,848 98.9%   
Current liabilities Rs m6,50720,897 31.1%   
Net working cap to sales %99.827.4 364.5%  
Current ratio x7.02.2 317.7%  
Inventory Days Days12757 223.1%  
Debtors Days Days9551 186.8%  
Net fixed assets Rs m21,16065,498 32.3%   
Share capital Rs m531159 333.3%   
"Free" reserves Rs m58,62547,930 122.3%   
Net worth Rs m59,15648,089 123.0%   
Long term debt Rs m042,429 0.0%   
Total assets Rs m67,832114,685 59.1%  
Interest coverage x926.86.4 14,511.7%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.60.8 72.2%   
Return on assets %12.96.9 186.4%  
Return on equity %14.812.0 123.6%  
Return on capital %20.812.4 167.9%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35912,422 260.5%   
Fx outflow Rs m9,04217,227 52.5%   
Net fx Rs m23,317-4,805 -485.3%   
CASH FLOW
From Operations Rs m7,75911,215 69.2%  
From Investments Rs m-4,783-10,118 47.3%  
From Financial Activity Rs m-3,1426,574 -47.8%  
Net Cashflow Rs m-1667,612 -2.2%  

Share Holding

Indian Promoters % 52.0 45.6 114.0%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 11.8 8.7 135.6%  
FIIs % 19.0 21.2 89.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 21.1 81.5%  
Shareholders   31,796 23,815 133.5%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 13, 2019 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS